Trial Profile
A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Dec 2023
Price :
$35
*
At a glance
- Drugs Patisiran (Primary)
- Indications Familial amyloid neuropathy
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms APOLLO-OLE
- Sponsors Alnylam Pharmaceuticals
- 15 Sep 2022 Status changed from active, no longer recruiting to completed.
- 13 Sep 2022 Planned End Date changed from 1 Aug 2022 to 31 Dec 2022.
- 08 Sep 2022 Results published in the Media Release